Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study.
about
HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trialImpact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir GelDistinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue.Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.Newly Acquired Infection with Multi-Drug Resistant HIV-1 in a Patient Adherent to Pre-Exposure Prophylaxis.An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques.A Comparative Pre-Phase I Study of the Impact of Gel Vehicle Volume on Distal Colon Distribution, User Experience, and Acceptability.Use of Pharmacokinetic Data in Novel Analyses to Determine the Effect of Topical Microbicides as Preexposure Prophylaxis Against HIV Infection.Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy: the DOT-DBS Study.The validity of self-reported antiretroviral use in persons living with HIV: a population-based study.Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time Monitoring.Recent advances in pre-exposure prophylaxis for HIV.Label-Free Measurements of Tenofovir Diffusion Coefficients in a Microbicide Gel Using Raman Spectroscopy.Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir
P2860
Q33848307-09C42D9E-E322-4AAD-B2AF-BB1E2FC33BBDQ36446138-7A61F5FE-8C7C-41F2-9BBE-1BF1B56CAD39Q36888077-3511D66E-C6D8-44F7-9D90-90CA62A55F57Q37358658-A65104B3-A615-4779-B0DE-5B29C163DA5DQ38851078-A2EAD9FB-6F76-4DC5-B262-B542E74D66E9Q40072965-4BC01B5C-53D6-4382-857E-23DFB83423CFQ40165275-B674A57F-DEDE-4062-8669-CF8E74932BEAQ40460028-8BF43459-E37E-4D37-836A-B7F4CB2CF165Q43101128-453D05E9-4D53-4C04-93C0-4EF17D56E597Q46323872-1C3DC701-E008-494E-950B-EB03F35190AFQ47385522-2CAC47B4-CBEA-4E24-BB8D-62F4264639F5Q49587788-7401D599-912E-4C30-B81D-2270DC065CABQ49921922-49E3AFFC-C14D-4523-945D-B8C6A04C13B8Q50192323-7B3A3FA6-48FB-4FA9-A730-A3B82132D6CFQ53681301-59EA6696-3A07-476C-9E96-B014EB127DD7Q58787428-9FC3D819-26F4-4AD5-88BE-845FE559171E
P2860
Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Pharmacological Measures of Tr ...... Infection in the VOICE Study.
@ast
Pharmacological Measures of Tr ...... Infection in the VOICE Study.
@en
type
label
Pharmacological Measures of Tr ...... Infection in the VOICE Study.
@ast
Pharmacological Measures of Tr ...... Infection in the VOICE Study.
@en
prefLabel
Pharmacological Measures of Tr ...... Infection in the VOICE Study.
@ast
Pharmacological Measures of Tr ...... Infection in the VOICE Study.
@en
P2093
P2860
P356
P1476
Pharmacological Measures of Tr ...... Infection in the VOICE Study.
@en
P2093
Barbra A Richardson
Cliff Kelly
Craig W Hendrix
Elizabeth R Brown
James Y Dai
Mark Marzinke
Z Mike Chirenje
P2860
P304
P356
10.1093/INFDIS/JIV333
P407
P577
2015-06-29T00:00:00Z